KRAS mutated tumours with co-occurring mutations in the TP53 gene (reported frequency of 39–42%), on the other hand, are associated with active inflammation, high expression of PD-L1 and increased response to ICI [12,13,30,33,34]. This evidence concerns the gene KRAS and neoplasm.